Augmented renal clearance and therapeutic monitoring of β-lactams

International Journal of Antimicrobial Agents

Volumn 45, Issue 4, 2015, Pages 331-333

  Udy, Andrew A ^a   De Waele, Jan J ^b   Lipman, Jeffrey ^c,d  

^a Department of Intensive Care and Hyperbaric Medicine ^*  (Australia)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Augmented renal clearance; Therapeutic drug monitoring; Lactam antibiotics

Indexed keywords

BETA LACTAM DERIVATIVE; CEFEPIME; IMIPENEM; MEROPENEM; PIPERACILLIN; ANTIINFECTIVE AGENT; BETA LACTAM;

ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG MONITORING; GLOMERULUS FILTRATION RATE; KIDNEY CLEARANCE; KIDNEY FUNCTION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; BACTERIAL INFECTIONS; CRITICAL ILLNESS; FEMALE; HUMAN; MALE;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMS; CRITICAL ILLNESS; FEMALE; HUMANS; MALE;

EID: 84925511152     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.12.020     Document Type: Editorial

References (33)

1. A.A. Udy, J.A. Roberts, and J. Lipman Clinical implications of antibiotic pharmacokinetic principles in the critically ill Intensive Care Med 39 2013 2070 2082
2. A. Kumar, D. Roberts, K.E. Wood, B. Light, J.E. Parrillo, and S. Sharma Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock Crit Care Med 34 2006 1589 1596
3. J.A. Roberts, W.W. Hope, and J. Lipman Therapeutic drug monitoring of β-lactams for critically ill patients: unwarranted or essential? Int J Antimicrob Agents 35 2010 419 420
4. J.A. Roberts, M. Ulldemolins, M.S. Roberts, B. McWhinney, J. Ungerer, and D.L. Paterson Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept Int J Antimicrob Agents 36 2010 332 339
5. Y. Hayashi, J. Lipman, A.A. Udy, M. Ng, B. McWhinney, and J. Ungerer β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia Int J Antimicrob Agents 41 2013 162 166
6. J.A. Roberts, V. Stove, J. De Waele, B. Sipinkoski, B. McWhinney, and J. Ungerer Variability of protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI study Int J Antimicrob Agents 43 2014 423 430
7. G.S. Casu, M. Hites, F. Jacobs, F. Jacobs, F. Cotton, and F. Wolff Can changes in renal function predict variations in β-lactam concentrations in septic patients? Int J Antimicrob Agents 42 2013 422 428
8. U. Tröger, A. Drust, J. Martens-Lobenhoffer, I. Tanev, R.C. Braun-Dullaeus, and S.M. Bode-Böger Decreased meropenem levels in intensive care unit patients with augmented renal clearance: benefit of therapeutic drug monitoring Int J Antimicrob Agents 40 2012 370 372
9. J.A. Roberts, G.M. Joynt, G.Y. Choi, C.D. Gomersall, and J. Lipman How to optimise antimicrobial prescriptions in the intensive care unit: principles of individualised dosing using pharmacokinetics and pharmacodynamics Int J Antimicrob Agents 39 2012 187 192
10. N. Blondiaux, F. Wallet, R. Favory, T. Onimus, S. Nseir, and R.J. Courcol Daily serum piperacillin monitoring is advisable in critically ill patients Int J Antimicrob Agents 35 2010 500 503
11. T. Yagi, T. Naito, M. Doi, O. Nagura, T. Yamada, and M. Maekawa Plasma exposure of free linezolid and its ratio to minimum inhibitory concentration varies in critically ill patients Int J Antimicrob Agents 42 2013 329 334
12. J.J. De Waele, I. Danneels, P. Depuydt, J. Decruyenaere, M. Bourgeois, and E. Hoste Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion Int J Antimicrob Agents 41 2013 434 438
13. A. Jeurissen, I. Sluyts, and R. Rutsaert A higher dose of vancomycin in continuous infusion is needed in critically ill patients Int J Antimicrob Agents 37 2011 75 77
14. J.A. Roberts, S.K. Paul, M. Akova, M. Bassetti, J.J. De Waele, and G. Dimopoulos DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58 2014 1072 1083
15. J.P. Baptista, E. Sousa, P.J. Martins, and J.M. Pimentel Augmented renal clearance in septic patients and implications for vancomycin optimisation Int J Antimicrob Agents 39 2012 420 423
16. A.A. Udy, M.T. Putt, S. Shanmugathasan, J.A. Roberts, and J. Lipman Augmented renal clearance in the intensive care unit: an illustrative case series Int J Antimicrob Agents 35 2010 606 608
17. A. Huttner, E. Von Dach, A. Renzoni, B.D. Huttner, M. Affaticati, and L. Pagani Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study Int J Antimicrob Agents 2015 [typesetter: please add the details IJAA article 14-00788].
18. A.A. Udy, J.M. Varghese, M. Altukroni, S. Briscoe, B.C. McWhinney, and J.P. Ungerer Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations Chest 142 2012 30 39
19. M. Carlier, S. Carrette, J.A. Roberts, V. Stove, A.G. Verstraete, and E. Hoste Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care 17 2013 R84
20. A.A. Udy, J.P. Baptista, N.L. Lim, G.M. Joynt, P. Jarrett, and L. Wockner Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations Crit Care Med 42 2014 520 527
21. J.M. Conil, B. Georges, O. Mimoz, E. Dieye, S. Ruiz, and P. Cougot Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients Intensive Care Med 32 2006 2063 2066
22. M. Carlier, A. Dumoulin, A. Janssen, S. P.Icavet, S. Van Thuyne, and R. Van Eynde Comparison of different equations to assess glomerular filtration in critically ill patients Intensive Care Med 2015 (in press)
23. M. Carlier, S. Carrette, V. Stove, A.G. Verstraete, and J.J. De Waele Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course Int J Antimicrob Agents 43 2014 470 473
24. J.L. Vincent, J. Rello, J. Marshall, E. Silva, A. Anzueto, and C.D. Martin International study of the prevalence and outcomes of infection in intensive care units JAMA 302 2009 2323 2329
25. G.W. Procop Molecular diagnostics for the detection and characterization of microbial pathogens Clin Infect Dis 45 2007 S99 S111
26. G.L. Drusano, W. Liu, S. Fikes, R. Cirz, N. Robbins, and S. Kurhanewicz Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model J Infect Dis 210 2014 1319 1324
27. L. Lorente, L. Lorenzo, M.M. Martín, A. Jiménez, and M.L. Mora Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to Gram-negative bacilli Ann Pharmacother 40 2006 219 223
28. L. Lorente, A. Jiménez, S. Palmero, J.J. Jiménez, J.L. Iribarren, and M. Santana Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review Clin Ther 29 2007 2433 2439
29. L. Lorente, A. Jiménez, M.M. Martín, J.L. Iribarren, J.J. Jiménez, and M.L. Mora Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion Int J Antimicrob Agents 33 2009 464 468
30. T.P. Lodise Jr., B. Lomaestro, and G.L. Drusano Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy Clin Infect Dis 44 2007 357 363
31. J.J. De Waele, S. Carrette, M. Carlier, V. Stove, J. Boelens, and G. Claeys Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial Intensive Care Med 40 2014 380 387
32. J.A. Roberts, P. Kruger, D.L. Paterson, and J. Lipman Antibiotic resistance - what's dosing got to do with it? Crit Care Med 36 2008 2433 2440
33. K.J. Eagye, M.A. Banevicius, and D.P. Nicolau Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy Crit Care Med 40 2012 1329 1332